Agilent, GKSP-313, AdvanceBio APTS G2FS2 α(2,6) / FA2G2S(6)2 N-glycan Standard

AdvanceBio APTS G2FS2 α(2,6) / FA2G2S(6)2 N-glycan Standard. N-glycan (di-α(2,6)-sialylated, galactosylated biantennary, core-substituted with fucose) labeled with 8-aminopyrene-1,3,6-trisulfonate (APTS), for use as a qualitative standard in applications such as capillary electrophoresis (CE). Alternative glycan name: FA2G2S2, F(6)A2G(4)2S(6)2.

Specifications:
Chemical Structure:
Label: APTS
Monoisotopic Mass: MWGlycan + 440.9647 = 2809.8056
Name: G2FS2 (α2,6)
Oxford Name: F(6)A2G2S(6)2
Standard Type: Complex-type Native N-Glycan
Unit: 60 pmol

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
This specialized N-glycan standard is designed for confident quantitation and structural verification in glycan analysis workflows. It contains highly purified, well-characterized APTS-labeled G2FS2 α(2,6) / FA2G2S(6)2 species, enabling researchers to accurately identify and quantify sialylated, fucosylated N-glycans in biopharmaceutical and glycomics studies. Suitable for method development, system suitability testing, and calibration, the standard supports both qualitative and quantitative accuracy in analytical procedures.

Optimized for compatibility with CE-LIF (capillary electrophoresis with laser-induced fluorescence detection) and HILIC-UPLC systems, it integrates seamlessly into high-throughput, high-resolution workflows such as those using the Agilent 1290 Infinity LC series or the 7100 Capillary Electrophoresis system. The standard serves as a benchmark for glycan profiling of complex biological samples, monoclonal antibodies, and therapeutic proteins, facilitating regulatory compliance and lot-to-lot consistency assessments.

It is best employed alongside other well-characterized N-glycan standards from the AdvanceBio portfolio to enable comprehensive glycan mapping. Researchers involved in characterization, quality control, or comparability assessments in the pharmaceutical and biotechnology industries will benefit from its reliability and reproducibility in structural elucidation and routine analysis.